GLP1R and type 2 diabetes mellitus: The results indicated that patients with T2D treated with GLP-1 RAs vs. insulin had a significant risk reduction (by about 25 to 65%) in 10 of the 13 OACs, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer.